Press Releases Adagene Inc.

Equities

ADAG

US0053291078

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-07 pm EDT			5-day change	1st Jan Change
2.246 ^USD	-2.79%		-0.64%	+16.26%

Mar. 29	Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 29	Adagene Inc. Announces Board Changes	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adagene : Entry into Sales Agreement - Form 6-K	Mar. 29	PU
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update	Mar. 29	GL
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board	Mar. 07	GL
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	Feb. 27	GL
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	Feb. 27	AQ
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	Feb. 09	GL
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	Jan. 16	GL
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	Jan. 16	AQ
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium	Jan. 04	GL
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium	Jan. 04	AQ
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023	Nov. 03	GL
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023	Nov. 03	AQ
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	23-10-12	GL
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting	23-10-12	AQ
Adagene : Departure of Chief Technology Officer - Form 6-K	23-09-29	PU
Adagene to Present at Investor and Scientific Conferences in September	23-09-07	GL
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update	23-08-31	AQ
Adagene : Anti-CTLA-4 Candidates Overview	23-07-10	PU
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate	23-05-04	GL
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate	23-05-04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Adagene Inc.

Equities

ADAG

US0053291078

Press Releases

Filters